Advanced Proteome Therapeutics Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APTCF research report →
Price Chart
About the company
Advanced Proteome Therapeutics Corporation, operating through its subsidiary Advanced Proteome Therapeutics Inc. , functions as a biotechnology company based in the United States. Its core business involves the creation and commercialization of a unique platform designed for the chemical modification of protein-based treatments.
- CEO
- Benjamin Krantz
- IPO
- 2009
- HQ
- Burnaby, BC, CA
Get TickerSpark's AI analysis on APTCF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $149.63K
- P/E
- 0.01
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.01
- EV/EBITDA
- 0.07
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 198.18%
- ROIC
- 186.68%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-4,597-55.5%
- Op Income
- $-940,859
- Net Income
- $759.62K+141.4%
- EPS
- $0.02+132.7%
- OCF Growth
- -27.2%
- FCF Growth
- -29.3%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.41
- RSI (14)
- 1
- Avg Volume
- 9.99K
No earnings-call transcripts are available for APTCF yet.
- Free Float
- 5.0%
- Shares Outstanding
- 748.15M
- Float Shares
- 37.15M
Our APTCF coverage
Recent articles, reports, and earnings notes.
No research on APTCF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APTCF report →